Scholarlink

Objectives <p>To investigate the performance of Diffusion levels (DLs) in diagnosing clinically significant prostate cancer (csPCa) when combined with the PI-RADS version 2.1.</p> Materials and methods <p>This retrospective, bicentric study included 261 men who underwent 3.0-T prostate MRI between March 2020 and April 2023, receiving systematic and target prostate biopsy on PI-RADS ≥ 3 lesions. Two readers measured the Apparent diffusion coefficient (ADC) of PI-RADS 1–5 findings in the peripheral zone. By plotting the cumulative frequency of csPCa versus ADCs and using ROC analysis, we derived four DLs expressing levels of restricted diffusion, i.e., very low DL (VL-DL), low DL (L-DL), intermediate DL (I-DL), and high DL (H-DL). We compared the per-lesion diagnostic performance in assessing csPCa (grading group ≥ 2 cancer) assuming to biopsy PI-RADS ≥ 3 lesions (strategy 1), PI-RADS ≥ 3 lesions adjusted with ADC values (strategy 2–4), and PI-RADS ≥ 3 lesions adjusted with DLs (strategy 5–7). Net benefit was assessed with decision curve analysis.</p> Results <p>csPCa was found in 79/261 men (30.3%) and 152/528 lesions (28.8%). There was a negative correlation (<i>p</i> &lt; 0.0001) between ADC versus malignancy rate (tau −0.970) and DLs versus csPCa grading group (tau −0.614). csPCa prevalence was highest in VL-DL (72.2%) and L-DL (54.4%). Most DLs-based strategies increased specificity, positive predictive value (PPV), and net benefit compared to ADC-based strategies or PI-RADS alone. The best strategy showed 94.7% sensitivity, 82.9% specificity, 69.2% PPV, and 97.5% negative predictive value.</p> Conclusion <p>While larger-scale validation is needed, DLs have the potential to improve PI-RADS-based biopsy decisions for detecting csPCa in the peripheral zone.</p> Key Points <p><Emphasis Type="BoldItalic">Question</Emphasis> <i>It is still unclear how to incorporate quantitative information from diffusion-weighted imaging (DWI) into prostate MRI.</i></p> <p><Emphasis Type="BoldItalic">Findings</Emphasis> <i>Combining DWI-derived diffusion levels (DLs) with the PI-RADS version 2.1 categorization reduced false positives while preserving high sensitivity for clinically significant prostate cancer.</i></p> <p><Emphasis Type="BoldItalic">Clinical relevance</Emphasis> <i>DLs permit to easily account for ADC values of prostate lesions and, in turn, refine biopsy decisions.</i></p> Graphical Abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Diffusion levels for quantitative assessment of the apparent diffusion coefficient value in prostate MRI: a proof-of-concept bicentric study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年4月7日

查看全文
  • Rossano Girometti,
  • Valeria Peruzzi,
  • Paola Clauser,
  • Nina Pötsch,
  • Maria De Martino,
  • Miriam Isola,
  • Gianluca Giannarini,
  • Alessandro Crestani,
  • Chiara Zuiani,
  • Lorenzo Cereser,
  • Pascal AT Baltzer

摘要

Objectives

To investigate the performance of Diffusion levels (DLs) in diagnosing clinically significant prostate cancer (csPCa) when combined with the PI-RADS version 2.1.

Materials and methods

This retrospective, bicentric study included 261 men who underwent 3.0-T prostate MRI between March 2020 and April 2023, receiving systematic and target prostate biopsy on PI-RADS ≥ 3 lesions. Two readers measured the Apparent diffusion coefficient (ADC) of PI-RADS 1–5 findings in the peripheral zone. By plotting the cumulative frequency of csPCa versus ADCs and using ROC analysis, we derived four DLs expressing levels of restricted diffusion, i.e., very low DL (VL-DL), low DL (L-DL), intermediate DL (I-DL), and high DL (H-DL). We compared the per-lesion diagnostic performance in assessing csPCa (grading group ≥ 2 cancer) assuming to biopsy PI-RADS ≥ 3 lesions (strategy 1), PI-RADS ≥ 3 lesions adjusted with ADC values (strategy 2–4), and PI-RADS ≥ 3 lesions adjusted with DLs (strategy 5–7). Net benefit was assessed with decision curve analysis.

Results

csPCa was found in 79/261 men (30.3%) and 152/528 lesions (28.8%). There was a negative correlation (p < 0.0001) between ADC versus malignancy rate (tau −0.970) and DLs versus csPCa grading group (tau −0.614). csPCa prevalence was highest in VL-DL (72.2%) and L-DL (54.4%). Most DLs-based strategies increased specificity, positive predictive value (PPV), and net benefit compared to ADC-based strategies or PI-RADS alone. The best strategy showed 94.7% sensitivity, 82.9% specificity, 69.2% PPV, and 97.5% negative predictive value.

Conclusion

While larger-scale validation is needed, DLs have the potential to improve PI-RADS-based biopsy decisions for detecting csPCa in the peripheral zone.

Key Points

Question It is still unclear how to incorporate quantitative information from diffusion-weighted imaging (DWI) into prostate MRI.

Findings Combining DWI-derived diffusion levels (DLs) with the PI-RADS version 2.1 categorization reduced false positives while preserving high sensitivity for clinically significant prostate cancer.

Clinical relevance DLs permit to easily account for ADC values of prostate lesions and, in turn, refine biopsy decisions.

Graphical Abstract